News FDA knocks back Biogen's high-dose Spinraza Biogen's efforts to defend its SMA business have been dealt a setback after the FDA declined to approve a high-dose version of Spinraza.
News Lilly names Houston as site for $6.5bn API facility Lilly has named Houston as the second of four locations for new manufacturing facilities that are central to a $27bn investment programme in the US.
News Manufacturing issues block FDA nod for Scholar Rock SMA drug Unresolved issues at a manufacturing plant operated by Novo Nordisk have led to a complete response letter for Scholar Rock's SMA drug apitegromab.
News BMS says it will set Cobenfy's UK price the same as the US Bristol Myers Squibb's price tag for schizophrenia drug Cobenfy in the UK is a manifestation of Trump's most favoured nation drug pricing policy.
News Alarm as Trump peddles unproven causes of autism Medical groups have reacted with dismay after Trump linked childhood vaccinations and use of acetaminophen to autism.
News Stealth's patience rewarded as FDA approves Barth drug After a long haul, Stealth BioTherapeutics has finally claimed FDA approval for Forzinity, the first treatment for ultra-rare disease Barth syndrome.
News Otsuka grows in neuroplastogens with $1.225bn Transcend buy Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
